Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-488 Phase I in Healthy Subjects and Psoriasis Patients
NCT05451199Phase 1Unknown
- Sponsor
- InnoCare Pharma
- Start
- Jul 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis comparing ICP-488 with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events at Day 28. Status: unknown.
02
Drugs
icp-488
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05451199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451199.